Onward Medical Launches Capital Increase Through Private Placement
Onward Medical has announced the launch of a capital increase through a private placement with institutional investors, aiming to raise approximately 50 million euros.
According to the press release, Onward Medical seeks to raise gross funds of approximately 50 million euros through a private placement of new ordinary shares. The share price will be determined at the end of the book-building process.
Utilization of Funds
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Onward Medical plans to use the net proceeds from this placement to fund various projects, including product development, clinical studies, and regulatory activities for the ARC-IM system, aimed at treating blood pressure instability in individuals with spinal cord injuries. About 40% of the funds will be allocated to these initiatives, 30% to the expansion of sales and operations to support the commercialization of the ARC-EX system, 20% to quality and administrative activities, and 10% for working capital, financial costs, and existing obligations.
Book-Building and Listing Details
The book-building period for this private placement is expected to last one business day, allowing for broader investor participation. The new shares are expected to be listed on Euronext in Brussels, Amsterdam, and Paris on October 28, 2025. The company has obtained approval from the Financial Services and Markets Authority of Belgium to temporarily suspend trading of its shares during this period.
“We continued to deliver strong commercial execution in Q3, and we achieved several meaningful scientific and regulatory milestones across our technology platforms.”
Commercial traction forte avec 40 systèmes ARC-EX vendus en Q3 et disponibilité dans plus de 60 cliniques US; CE Mark pour l'UE et clearance FDA pour usage à domicile élargissent l'opportunité commerciale; IDE approuvé pour ARC-IM permettant le lancement de l'étude pivot Empower BP; publications scientifiques majeures renforcent le dossier clinique.
Risks mentioned
retards dans les autorisations réglementaires
variations de la demande commerciale
concurrence technologique et concurrentielle
incertitudes liées aux études cliniques et résultats futurs
Opportunities identified
FDA clearance for home use expands US market opportunity
CE Mark enables commercialization in EU and facilitates entry to UK and Switzerland
IDE approval for ARC-IM enables initiation of Empower BP pivotal study
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
